Anti-nausea drug could help treat sleep apnea

June 06, 2017

An old pharmaceutical product may be a new treatment for obstructive sleep apnea, according to new research presented today by University of Illinois at Chicago and Northwestern University scientists at the SLEEP 2017 annual meeting in Boston.

David Carley, professor of biobehavioral health sciences, medicine and bioengineering at UIC; Phyllis Zee, professor of neurology at Northwestern University; and their colleagues have discovered that dronabinol, approved by the U.S. Food and Drug Administration more than 25 years ago to treat nausea and vomiting in chemotherapy patients, can help people who suffer from sleep apnea.

"At the present time there are no approved drug treatments for sleep apnea, and there remains an important unmet need for fully effective and acceptable treatments of the disorder," said Carley.

Obstructive sleep apnea is a condition where breathing is briefly but repeatedly interrupted during sleep. It occurs when the throat muscles fail to keep the airway open during sleep, despite efforts to breathe. An estimated 22 million Americans suffer from the disorder, with 80 percent of the cases of moderate and severe obstructive sleep apnea undiagnosed.

Sleep related breathing disorders, especially obstructive sleep apnea, pose significant health problems. Individuals suffering from sleep apnea have an increased risk for coronary heart disease, stroke, high blood pressure and type 2 diabetes.

In a previous study, Carley found dronabinol, a cannabinoid agonist, held significant potential for treating sleep apnea.

Expanding on this research, Carley and Zee received a federal grant to initiate the Pharmacotherapy of Apnea by Cannabimimetic Enhancement (PACE) study. It is the largest National Institutes of Health-sponsored randomized controlled trial of any existing drug treatment for obstructive sleep apnea syndrome to date.

Adult patients were divided into three groups. One group was given a low dose of the drug, a second group received a higher dose, and the third, a placebo. Participants received the drug once daily before bed for six weeks.

"In comparison to placebo, six weeks of treatment by the highest dose of dronabinol (10 milligrams) was associated with a lower frequency of apneas or hypopneas during sleep, decreased subjective sleepiness, and greater overall treatment satisfaction," Carley said. "Neither the amount of sleep nor objective sleepiness improved."

UIC has licensed intellectual property related to the experimental drug treatment used in the study to the pharmaceutical company RespireRx.

Researchers have attempted to identify drugs to treat sleep apnea for nearly 35 years, but to no avail, Carley said.

"By providing a path toward the first viable obstructive sleep apnea drug, our studies could have a major impact on clinical practice," he said. "However, expanded and pivotal clinical trials must still be conducted to fully establish the best approach to cannabinoid therapy in obstructive sleep apnea."
-end-
Carley and Zee's research colleagues include Bharati Prasad, Boris Vern, Hui Xie, and Chenbgo Yuan, all of UIC; and Kathryn Jean Reid, Roneil Malkani, Hrayr Attarian, and Sabra Abbott, all of Northwestern.

University of Illinois at Chicago

Related Sleep Apnea Articles from Brightsurf:

Sleep apnea may be risk factor for COVID-19
The question of sleep apnea as the risk factor for COVID-19 arose in a study conducted by the Turku University Hospital and the University of Turku on patients of the first wave of the pandemic.

Untreated sleep apnea is associated with flu hospitalization
As we approach flu season, adults with obstructive sleep apnea may want to take extra precautions.

Losing tongue fat improves sleep apnea
Using magnetic resonance imaging (MRI) to measure the effect of weight loss on the upper airway in obese patients, researchers found that reducing tongue fat is a primary factor in lessening the severity of OSA.

More cancer cases among women with sleep apnea
Women with severe sleep apnea appear to be at an elevated risk of getting cancer, a study shows.

New evidence on the association of shortened sleep time and obstructive sleep apnea with sleepiness and cardiometabolic risk factors
A new study in the journal CHEST® may change the way we think about sleep disorders.

Synthetic cannabis-like drug reduces sleep apnea
A synthetic cannabis-like drug in a pill reduced apnea and daytime sleepiness in the first large multi-site study of a drug for apnea.

Inflammation may precede sleep apnea, could be treatment target
Inflammation is traditionally thought of as a symptom of sleep apnea, but it might actually precede the disorder, potentially opening the door for new ways to treat and predict sleep apnea, according to researchers.

Concerns that sleep apnea could impact healthspan
The number of people with obstructive sleep apnea has steadily increased over the past two decades.

Sleep apnea and insomnia combination linked with depression
A new study found that men with sleep apnea and insomnia have a higher prevalence and severity of depressive symptoms than men with sleep apnea or insomnia alone.

Anti-nausea drug could help treat sleep apnea
An old pharmaceutical product may be a new treatment for obstructive sleep apnea, according to new research presented today by University of Illinois at Chicago and Northwestern University scientists at the SLEEP 2017 annual meeting in Boston.

Read More: Sleep Apnea News and Sleep Apnea Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.